Technical Analysis for KMPH - KemPharm, Inc.

Grade Last Price % Change Price Change
grade C 5.95 -4.80% -0.30
KMPH closed down 4.8 percent on Friday, June 15, 2018, on 4.16 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical KMPH trend table...

Date Alert Name Type % Chg
Jun 15 Fell Below 50 DMA Bearish 0.00%
Jun 15 Volume Surge Other 0.00%
Jun 15 Stochastic Reached Oversold Weakness 0.00%
Jun 15 Down 3 Days in a Row Weakness 0.00%
Jun 15 Down 4 Days in a Row Weakness 0.00%
Jun 15 Oversold Stochastic Weakness 0.00%
Jun 14 MACD Bearish Signal Line Cross Bearish -4.80%
Jun 14 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.80%
Jun 14 Down 3 Days in a Row Weakness -4.80%
Jun 12 Bearish Engulfing Bearish -10.53%

Older signals for KMPH ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
Basic chart:

Profile
KemPharm is a specialty pharmaceutical company focused on the discovery and development of NME prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high needs areas of pain, ADHD and other CNS disorders.
Is KMPH a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
May 23 Janney Buys Into KemPharm Ahead Of 'Transformative' Summer Catalyst
May 23 Benzinga's Top Upgrades, Downgrades For May 23, 2018
May 18 Who Are The Major Shareholders In KemPharm Inc (NASDAQ:KMPH)?
May 16 FDA OKs first non-opioid treatment for opioid withdrawal
May 14 KemPharm: Patients Not Liking Their Drugs Is Great News
May 12 KemPharm's (KMPH) CEO Travis Mickle on Q1 2018 Results - Earnings Call Transcript
May 11 KemPharm Stock Breaks Out on Clinical Trial Results
May 11 Will KemPharm Inc’s (NASDAQ:KMPH) Earnings Grow Over The Next Few Years?
May 10 KemPharm misses by $1.07
May 10 KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results
See more KMPH news...
Indicators
Indicator Value
52 Week High 8.4
52 Week Low 2.45
Average Volume 99,697
200-Day Moving Average 5.0498
50-Day Moving Average 6.0146
20-Day Moving Average 6.4275
10-Day Moving Average 6.565
Average True Range 0.3688
ADX 20.0
+DI 18.22
-DI 22.67
Chandelier Exit (Long, 3 ATRs ) 6.0436
Chandelier Exit (Short, 3 ATRs ) 7.0564
Upper Bollinger Band 6.9599
Lower Bollinger Band 5.8951
Percent B (%b) 0.05
BandWidth 16.566317
MACD Line 0.1123
MACD Signal Line 0.1747
MACD Histogram -0.0624
Fundamentals Value
Market Cap 87.21 Million
Num Shares 14.7 Million
EPS -3.10
Price-to-Earnings (P/E) Ratio -1.92
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.63
Resistance 3 (R3) 6.70 6.55 6.51
Resistance 2 (R2) 6.55 6.38 6.51 6.47
Resistance 1 (R1) 6.25 6.27 6.18 6.18 6.44
Pivot Point 6.10 6.10 6.06 6.06 6.10
Support 1 (S1) 5.80 5.93 5.73 5.73 5.46
Support 2 (S2) 5.65 5.82 5.61 5.43
Support 3 (S3) 5.35 5.65 5.39
Support 4 (S4) 5.28